ARTICLE | Company News
Genmab acquires cancer targets
May 19, 2005 12:08 AM UTC
Genmab (CSE:GEN) acquired rights to 16 cancer targets to treat non-steroid dependent cancers of epithelial cell origin, such as gastrointestinal cancers, from the insolvency administrator of Europrote...